Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$75.82 - $150.97 $137,234 - $273,255
-1,810 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$132.01 - $190.29 $238,938 - $344,424
1,810 New
1,810 $266,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Nan Fung Group Holdings LTD Portfolio

Follow Nan Fung Group Holdings LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nan Fung Group Holdings LTD, based on Form 13F filings with the SEC.

News

Stay updated on Nan Fung Group Holdings LTD with notifications on news.